Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Different-dose methylprednisolone for myasthenia gravis
ChiCTR1800018623Phase 4Recruiting
- Sponsor
- People's Hospital of Shijiazhuang
- Start
- Oct 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of methylprednisolone in myasthenia gravis (MG), sponsored by People's Hospital of Shijiazhuang. Primary endpoint: Remission rate. Started Oct 2018; status: recruiting.
02
Drugs
methylprednisolone
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on ChiCTR1800018623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018623.